Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTUDPCI)

• DTT Name: Neurotrophic tyrosine kinase ROR2 (ROR2)
• Synonyms: receptor tyrosine kinase like orphan receptor 2; neurotrophic tyrosine kinase, receptor-related 2; Tyrosine-protein kinase transmembrane receptor ROR2; NTRKR2; BDB1; BDB
• Gene Name: ROR2
• DTT Type: Clinical trial target; [1]
• BioChemical Class: Kinase
• UniProt ID: ROR2_HUMAN
• TTD ID: T91435
• EC Number: EC 2.7.10.1
• Sequence:
  MARGSALPRRPLLCIPAVWAAAALLLSVSRTSGEVEVLDPNDPLGPLDGQDGPIPTLKGY
  FLNFLEPVNNITIVQGQTAILHCKVAGNPPPNVRWLKNDAPVVQEPRRIIIRKTEYGSRL
  RIQDLDTTDTGYYQCVATNGMKTITATGVLFVRLGPTHSPNHNFQDDYHEDGFCQPYRGI
  ACARFIGNRTIYVDSLQMQGEIENRITAAFTMIGTSTHLSDQCSQFAIPSFCHFVFPLCD
  ARSRTPKPRELCRDECEVLESDLCRQEYTIARSNPLILMRLQLPKCEALPMPESPDAANC
  MRIGIPAERLGRYHQCYNGSGMDYRGTASTTKSGHQCQPWALQHPHSHHLSSTDFPELGG
  GHAYCRNPGGQMEGPWCFTQNKNVRMELCDVPSCSPRDSSKMGILYILVPSIAIPLVIAC
  LFFLVCMCRNKQKASASTPQRRQLMASPSQDMEMPLINQHKQAKLKEISLSAVRFMEELG
  EDRFGKVYKGHLFGPAPGEQTQAVAIKTLKDKAEGPLREEFRHEAMLRARLQHPNVVCLL
  GVVTKDQPLSMIFSYCSHGDLHEFLVMRSPHSDVGSTDDDRTVKSALEPPDFVHLVAQIA
  AGMEYLSSHHVVHKDLATRNVLVYDKLNVKISDLGLFREVYAADYYKLLGNSLLPIRWMA
  PEAIMYGKFSIDSDIWSYGVVLWEVFSYGLQPYCGYSNQDVVEMIRNRQVLPCPDDCPAW
  VYALMIECWNEFPSRRPRFKDIHSRLRAWGNLSNYNSSAQTSGASNTTQTSSLSTSPVSN
  VSNARYVGPKQKAPPFPQPQFIPMKGQIRPMVPPPQLYVPVNGYQPVPAYGAYLPNFYPV
  QIPMQMAPQQVPPQMVPKPSSHHSGSGSTSTGYVTTAPSNTSMADRAALLSEGADDTQNA
  PEDGAQSTVQEAEEEEEGSVPETELLGDCDTLQVDEAQVQLEA
• Function: It seems to be required for cartilage and growth plate development. Phosphorylates YWHAB, leading to induction of osteogenesis and bone formation. In contrast, has also been shown to have very little tyrosine kinase activity in vitro. May act as a receptor for wnt ligand WNT5A which may result in the inhibition of WNT3A-mediated signaling. Tyrosine-protein kinase receptor which may be involved in the early formation of the chondrocytes.
• KEGG Pathway: Wnt signaling pathway (hsa04310)
• Reactome Pathway:
  WNT5A-dependent internalization of FZD2, FZD5 and ROR2 (R-HSA-5140745)
  PCP/CE pathway (R-HSA-4086400)

Molecular Interaction Atlas (MIA) of This DTT

3 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ozuriftamab vedotin	DMOI00X	Head-neck squamous cell carcinoma	2D60.0	Phase 2	[2]
CCT301-38 (targeting ROR2)	DM2B1V0	Renal cell carcinoma	2C90	Phase 1/2	[1]
CCT301-59 (targeting ROR2)	DM0F9CD	Renal cell carcinoma	2C90	Phase 1/2	[1]

References

• [1] ClinicalTrials.gov (NCT03393936) Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma
• [2] Clinical pipeline report, company report or official report of BioAtla